Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells

Leukemia
H G Drexler

Abstract

The cyclin-dependent kinase inhibitors known as p15, p16, p18 and p19 have been suggested as candidates for tumor suppressor genes. The main genetic alterations are deletions (bi- or monoallelic) or 5' CpG island methylation of p15 and p16; very few cases or cell lines had p18 or p19 deletions or hypermethylation. Hypermethylation and homozygous deletions of tumor suppressor genes establish a new paradigm of inactivation by lack of expression, in contrast to the previously identified tumor suppressors which are predominantly inactivated by point mutations followed by loss of the wild-type allele. Here, the literature data on alterations of this gene family in more than 4700 primary cases of leukemia or lymphoma and some 320 continuous leukemia-lymphoma cell lines are summarized. Among hematopoietic malignancies, the highest frequencies of p15del and p16del were seen in acute lymphoblastic leukemia (ALL) (>30%) with striking rates in T-ALL (>50%), but also high rates in B cell precursor (BCP)-ALL (>20%); the rates of deletions in chronic lymphoid leukemia (CLL), multiple myeloma, acute and chronic myeloid leukemia (AML and CML), and myelodysplastic syndromes (MDS) were rather low, only some B cell and T cell lymphomas showed inc...Continue Reading

Citations

Feb 1, 2000·International Journal of Cancer. Journal International Du Cancer·J BartkovaJ Bartek
Mar 14, 2000·Reviews in Medical Virology·M Flint, J A McKeating
Dec 7, 2002·Hematological Oncology·C S ChimY L Kwong
May 7, 2002·International Journal of Cancer. Journal International Du Cancer·Kazuya KudohKazuhiko Uchida
Dec 23, 2003·International Journal of Hematology·Genoveffa FranchiniJake R Fullen
Feb 6, 2009·Journal of Applied Genetics·A M UdayakumarJ A Raeburn
Sep 7, 2007·Cancer Chemotherapy and Pharmacology·Vincenzo GuarcelloMahmoud H El Kouni
Sep 18, 2008·International Journal of Hematology·Elpis MantadakisMaria Kalmanti
Jun 1, 2005·Biochemical and Biophysical Research Communications·Adam GeminGurmit Singh
May 13, 2005·Mechanisms of Ageing and Development·Young Hoon SungHan-Woong Lee
Feb 6, 2004·Seminars in Cancer Biology·Alison M JohnRose Ann Padua
Feb 13, 2002·Leukemia Research·Hans G DrexlerRoderick A F MacLeod
Jul 20, 2002·Leukemia Research·Hans G Drexler, Roderick A F MacLeod
May 5, 2001·Pharmacology & Therapeutics·C R Weinstein-OppenheimerJ A McCubrey
Apr 13, 2001·Experimental Hematology·J R Fink, T W LeBien
Mar 20, 2003·Experimental Hematology·Juan-Carlos Hernández-BoludaEmilio Montserrat
Mar 11, 1999·Current Opinion in Genetics & Development·N E Sharpless, R A DePinho
Oct 18, 2003·Seminars in Cancer Biology·Christine Damm-WelkArndt Borkhardt
Aug 30, 2002·The International Journal of Biochemistry & Cell Biology·Géraldine CarrardBertrand Friguet
Oct 31, 2003·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Sriharsa Pradhan, Pierre-Olivier Esteve
Apr 16, 2005·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Hisashi TakinoHiroshi Inagaki
Jan 14, 1999·British Journal of Haematology·C J ChapmanF K Stevenson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.